Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 2/20 | 0.69 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3441348 | 0.91 | KAT2B (0.58) | KAT2BBAZ2BKCNH2CTNNB1IRAK4 | |
| SCHEMBL2486551 | 0.89 | KCNH2 (0.58) | KAT2BBAZ2BKCNH2CTNNB1IRAK4 | |
| SCHEMBL8890812 | 0.86 | KAT2B (0.71) | KAT2BBAZ2BKCNH2PDE4DHTT | |
| SCHEMBL7163802 | 0.85 | KCNH2 (0.56) | KAT2BBAZ2BKCNH2CTNNB1IRAK4 | |
| SCHEMBL1432308 | 0.85 | MKNK1 (0.56) | KAT2BBAZ2BKCNH2CTNNB1IRAK4 | |
| SCHEMBL13692329 | 0.84 | KAT2B (0.74) | KAT2BBAZ2BPDE4DPDE4APDE4B | |
| SCHEMBL22118181 | 0.84 | MKNK1 (0.56) | KAT2BBAZ2BKCNH2CTNNB1IRAK4 | |
| SCHEMBL20646728 | 0.83 | KCNH2 (0.53) | KAT2BBAZ2BKCNH2CTNNB1IRAK4 | |
| SCHEMBL19151444 | 0.83 | KCNH2 (0.53) | KAT2BBAZ2BKCNH2CTNNB1IRAK4 | |
| SCHEMBL27771962 | 0.83 | KCNH2 (0.53) | KAT2BBAZ2BKCNH2CTNNB1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4651714-B2 | — | — | 2011-03-16 | — | — | JP | claimed |
| EP-1902052-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-03-26 | — | — | EP | claimed |
| WO-2007007041-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | claimed |
| US-20260070887-A1 | AMIDE OR UREA COMPOUND | SHENZHEN ZHONGGE BIOLOGICAL TECH CO LTD (CN) | 2026-03-12 | — | — | US | disclosed |
| EP-4628486-A1 | AMIDE OR UREA COMPOUND | Shenzhen Zhongge Biological Technology Co., Ltd. (CN) | 2025-10-08 | — | — | EP | disclosed |
| WO-2024114787-A9 | AMIDE OR UREA COMPOUND | 深圳众格生物科技有限公司 | 2025-05-30 | — | — | WO | disclosed |
| CN-117412981-A | Phosphine oxide derivative and preparation method and application thereof | 希格生科（深圳）有限公司 | 2024-01-16 | — | — | CN | disclosed |
| EP-4267131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR PARASITIC DISEASES | CELGENE CORPORATION (US) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022146920-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR PARASITIC DISEASES | CELGENE CORPORATION (US) | 2022-07-07 | — | — | WO | disclosed |
| EP-1902052-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007007041-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070887-A1 | AMIDE OR UREA COMPOUND | KIF18A, KIF18B, KIF23 | KAT2B 709/4885BAZ2B 2179/4885KCNH2 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.